Regulatory approval
Published by the Health Canada. Approved
LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | BRCA1 pathogenic variants | Pancreatic Adenocarcinoma | Olaparib | |
| HC (1) | BRCA2 pathogenic variants | Pancreatic Adenocarcinoma | Olaparib |